Principles of medullary thyroid cancer staging according to AJCC TNM 8th edition
Aim. The research aims at analyzing the main changes in classification of medullary thyroid cancer and outlining the principles of staging according to modern studies.
Material and Methods. Specific scientific articles for the period of 2009-2019 referring to the principles and rules of the TNM classification process, as well as recommendations of the TNM committees of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (IUAC) were selected for the analysis. The basic principles of classification and staging for 8th edition of TNM, as well as changes that have taken place in comparison with 7th edition of TNM It were defined.
Results and Discussion. Medullary thyroid cancer accounts for 1-2 percent in the structure of cancers of the thyroid gland, however it is associated with a high mortality rate compared to highly differentiated forms of thyroid cancer. The main radical method of treatment is an adequate volume of surgical intervention, which is determined on the basis of proper staging, the use of visualization methods and the practical experience of doctors. The 7th edition of the TNM was introduced to the scientific society in 2009. It has been 10 years since a new version of the 8th edition based on the new data in evidence-based medicine appeared. It included numerous changes and additions, namely for medullary thyroid cancer. The following research suggests a detailed review and analysis of the basic principles of the staging and classification of medullary thyroid cancer for AJCC TNM-8 in order to improve the diagnosis and treatment of patients with the mentioned above disease.
Conclusions. The use of modern principles of classification and staging of medullary thyroid cancer in clinical practice promotes choosing the adequate treatment method and estimating the patient's prognosis. In addition, further improvement of the staging system by TNM-committee and cancer registers depends on the presence of detailed information on additional "parameters for collection and further evaluation" in medical documentation.
American Thyroid Association Guidelines Task F, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid : official journal of the American Thyroid Association. Jun 2009;19(6):565-612.
Bhansali A, Walia R, Rana SS, et al. Ectopic Cushing's syndrome: experience from a tertiary care centre. The Indian journal of medical research. Jan 2009;129(1):33-41.
Boichard A, Croux L, Al Ghuzlan A, et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. The Journal of clinical endocrinology and metabolism. Oct 2012;97(10):E2031-2035.
Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. Aug 2010;39(6):775-783.
Ciampi R, Mian C, Fugazzola L, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid : official journal of the American Thyroid Association. Jan 2013;23(1):50-57.
Davies L, Morris LG, Haymart M, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: The Increasing Incidence of Thyroid Cancer. Endocr Pract. Jun 2015;21(6):686-696.
Dralle H, Machens A. Surgical management of the lateral neck compartment for metastatic thyroid cancer. Current opinion in oncology. Jan 2013;25(1):20-26.
Elisei R, Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. Nature reviews. Endocrinology. Aug 2012;8(8):466-475.
Fetsych TG., Slipetskij RR. TNM-klasyfikacija, 7-me vydannja. - Lviv, 2014. - 169 p. Ukrainian
Frank-Raue K, Machens A, Leidig-Bruckner G, et al. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. Thyroid : official journal of the American Thyroid Association. Mar 2013;23(3):294-300.
Haddad RI. New developments in thyroid cancer. Journal of the National Comprehensive Cancer Network : JNCCN. May 2013;11(5 Suppl):705-707.
Halay OO., Slipetskij RR. Klinichni recomendaciji NCCN v onkolohiji: puchlyny holovy ta schyji, schytopodibnoji zalozy i schkiry. - Lviv, 2016. - 504 p. Ukrainian
Halay OO., Slipetskij RR. Zlojakisni puchlyny holovy ta schyji (TNM-atlas). - Lviv, 2014. - 127 p. Ukrainian
Kazaure HS, Roman SA, Sosa JA. Medullary thyroid microcarcinoma: a population-level analysis of 310 patients. Cancer. Feb 1 2012;118(3):620-627.
Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. The Journal of clinical endocrinology and metabolism. Jun 2010;95(6):2655-2663.
Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. The Journal of clinical endocrinology and metabolism. May 2011;96(5):E863-868.
Quan GM, Pointillart V, Palussiere J, Bonichon F. Multidisciplinary treatment and survival of patients with vertebral metastases from thyroid carcinoma. Thyroid : official journal of the American Thyroid Association. Feb 2012;22(2):125-130.
Raue F, Frank-Raue K. Genotype-phenotype correlation in multiple endocrine neoplasia type 2. Clinics (Sao Paulo). 2012;67 Suppl 1:69-75.
Rosen JE, Lloyd RV, Brierley JD, Grogan RH, Haddad R. et al. Thyroid - Medullary. In: AJCC Cancer Staging Manual, 8th ed. 2017, Corr. 3rd printing 2018 edition. Eds.: Amin MB, Edge SB, Greene FL, Byrd DR. Brookland RK., Springer, 2018, 899-910.
Toledo SP, Lourenco DM, Jr., Santos MA, Tavares MR, Toledo RA, Correia-Deur JE. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo). 2009;64(7):699-706.
Trimboli P, Cremonini N, Ceriani L, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. Clin Endocrinol (Oxf). Jan 2014;80(1):135-140.
Tuttle RM, Ball DW, Byrd D, et al. Medullary carcinoma. Journal of the National Comprehensive Cancer Network : JNCCN. May 2010;8(5):512-530.
Wells SA, Jr., Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid: official journal of the American Thyroid Association. Jun 2015;25(6):567-610.
Wexler JA. Approach to the thyroid cancer patient with bone metastases. The Journal of clinical endocrinology and metabolism. Aug 2011;96(8):2296-2307.
This work is licensed under a Creative Commons Attribution 4.0 International License.